MaxCyte, Inc. (MXCT) is a Medical - Devices company in the Healthcare sector, currently trading at $0.85. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is MXCT = $6 (+609.9% upside).
Valuation: MXCT trades at a trailing Price-to-Earnings (P/E) of -1.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.39.
Financials: revenue is $33M, -9.2%/yr average growth. Net income is $45M (loss), growing at -36.2%/yr. Net profit margin is -135.1% (negative). Gross margin is 68.4% (-20.1 pp trend).
Balance sheet: total debt is $18M against $171M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 8.3 (strong liquidity). Debt-to-assets is 8.9%. Total assets: $203M.
Analyst outlook: 4 / 6 analysts rate MXCT as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).
